Photo from wikipedia
Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious in phase 3 studies. Real‐world data for… Click to show full abstract
Optimally effective treatment for hepatitis C virus genotype 3 (GT3) is urgently needed, particularly in advanced liver disease. Daclatasvir plus sofosbuvir was efficacious in phase 3 studies. Real‐world data for daclatasvir+sofosbuvir in advanced GT3 infection are presented from the French Temporary Authorisation for Use programme, which allowed patients in need without other treatment options access to daclatasvir ahead of its market authorization.
Keywords:
daclatasvir;
daclatasvir plus;
plus sofosbuvir;
hepatitis virus;
virus genotype
Journal Title: Liver International
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Liver International
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!